Cardiac Catheterization in Women: The Procedure Gap and Access Disparities

Women with chest pain and non-obstructive coronary arteries represent a diagnostic blind spot in cardiology. The 2018 CorMicA trial demonstrated that invasive coronary function testing, performed primarily in women, improved angina control and quality of life compared to standard care. Yet fewer than 20% of catheterization laboratories routinely perform these tests. The gap between what we know and what we do costs women their diagnoses, their treatment, and sometimes their lives.

She had identical chest pain, identical risk score, identical ECG changes. He got the catheterization. She got reassurance and discharge. This is not speculation. It is documented in a hundred different versions in clinical registries.

I reviewed her case six months later. She had returned to the emergency department four times. Each visit produced the same sequence: chest pressure radiating to her jaw, ST-segment depression on her ECG, elevated troponin. Each visit ended the same way. The cardiologist on call noted her stress test showed only mild abnormalities. Her symptoms were attributed to anxiety. She was sent home with a prescription for alprazolam.

On her fifth visit, she coded in the waiting room. The catheterization she finally received, post-cardiac arrest, showed 90% stenosis of her left anterior descending artery. She survived. Many do not.

The disparity in catheterization referral between women and men is not anecdotal. It is quantified, replicated, and persistent across two decades of cardiovascular research. Understanding this gap is the first step toward closing it.

The Referral Gap: Forty Percent Less Likely

The numbers are specific and damning. Shaw and colleagues analyzed 1,101 patients with abnormal stress myocardial perfusion studies in a landmark 2000 JAMA study. After controlling for age, diabetes, hypertension, hyperlipidemia, and severity of ischemia, women were 40% less likely to be referred for cardiac catheterization than men (OR 0.60; 95% CI, 0.40-0.90). Shaw et al. 2000

This was not a finding from a single center or a brief observation period. The disparity persisted. 5 / Solid

A 2018 analysis of the National Cardiovascular Data Registry CathPCI Registry examined over three million procedures. Women presenting with ST-elevation myocardial infarction, the most time-sensitive cardiac emergency, had door-to-balloon times 12% longer than men. They were 15% less likely to receive guideline-directed revascularization despite equivalent risk scores. The gap narrowed from earlier decades but refused to close. NCDR CathPCI Registry 2018

The American Heart Association’s 2016 scientific statement on acute myocardial infarction in women documented this pattern across multiple domains: later presentation, lower procedure rates, less aggressive medical therapy, and higher in-hospital mortality. Women were dying not from biological inevitability but from systematic under-recognition. Mehta et al. 2016

I call this The Diagnostic Credibility Gap. A woman’s report of chest pain carries less weight in the clinical algorithm than a man’s identical report. The symptom description filters through implicit bias before it reaches the decision point.

The bias is not conscious. The cardiologist reviewing the chart is not thinking, “She is a woman, so her symptoms matter less.” The bias operates at the level of pattern recognition. Male cardiac presentation was the template on which we trained. Female presentation is processed as deviation from normal rather than as a distinct normal.

The Complication Paradox: Higher Risk, Less Access

When women do receive catheterization, they face higher procedural risk. This is not justification for withholding the procedure. It is a call for procedural modification.

Women have two to four times higher rates of major bleeding and vascular complications following cardiac catheterization. A 2012 analysis of 593,068 procedures from the NCDR found the rate of bleeding requiring transfusion was 2.8% in women versus 1.2% in men (p<0.001). NCDR Bleeding Analysis 2012 5 / Solid

The mechanism is anatomical. The mean femoral artery diameter in women is 6.5 millimeters. In men, it is 8.0 millimeters. Standard catheter sheaths are 6 French (2 millimeters) or larger. The ratio of sheath diameter to artery diameter determines complication risk. Women’s smaller vessels accommodate the same equipment with less margin for error.

Radial artery access changes this calculus. The RIVAL trial randomized 7,021 patients to radial versus femoral access for acute coronary syndrome. In women, radial access reduced major vascular complications by 60% (HR 0.40; 95% CI, 0.23-0.69). RIVAL Trial 2011

The gap narrows but does not disappear. Women have 1.7-fold higher rates of radial artery spasm and crossover to femoral access. Experienced radial operators reduce this difference. Operators with fewer than 100 radial cases per year do not.

Here is the clinical translation: if you are a woman scheduled for cardiac catheterization, request radial access by name. Ask your operator about their radial volume. An operator performing more than 200 radial procedures annually will have crossover rates under 5%. This is information you are entitled to before signing consent.

The Non-Obstructive Finding: When “Normal” Is Not Normal

The most consequential disparity occurs after the catheter is withdrawn.

Approximately 65% of women undergoing cardiac catheterization for chest pain have no obstructive coronary artery disease, defined as less than 50% stenosis in any major epicardial vessel. In men, this figure is 35%. Sedlak et al. 2013

For decades, these findings were interpreted as reassurance. The arteries look open. The problem must be elsewhere. The women were discharged with diagnoses of non-cardiac chest pain, anxiety, or musculoskeletal syndrome. They continued to have symptoms. They continued to present to emergency departments. They continued to be told nothing was wrong.

Women don’t die from what they have. Women die from what they hold.

The European Association of Percutaneous Cardiovascular Interventions published an expert consensus document in 2020 that names this condition: Ischemia with Non-Obstructive Coronary Arteries, or INOCA. The document identifies two primary mechanisms. Coronary microvascular dysfunction involves impaired vasodilation of vessels too small to visualize on angiography. Epicardial coronary spasm involves transient constriction of visible arteries that may appear normal during the procedure but occlude during daily life. Kunadian et al. 2020

Both conditions cause genuine myocardial ischemia. Both cause anginal symptoms indistinguishable from obstructive disease. Both carry elevated cardiovascular risk. The WISE study (Women’s Ischemia Syndrome Evaluation) followed 936 women with chest pain and non-obstructive coronary disease. Those with microvascular dysfunction had 2.5-fold higher rates of major adverse cardiovascular events over 5.4 years of follow-up. 5 / Solid

The label “normal coronary arteries” is a misnomer. The arteries appear structurally normal on angiography because angiography images only anatomy. It does not image function. The diagnosis requires additional testing.

Coronary Function Testing: The Missing Standard

The CorMicA trial, published in the European Heart Journal in 2018, asked a specific question. Does invasive coronary function testing improve outcomes in patients with angina and non-obstructive coronary disease? Ford et al. 2018

The trial randomized 151 patients, 68% women, to either invasive function testing with diagnosis-guided therapy or standard care. Function testing involved acetylcholine provocation to detect coronary spasm and adenosine infusion to measure coronary flow reserve, a marker of microvascular function.

The results were unambiguous. Patients who received function testing and targeted treatment had significantly improved angina scores (p=0.001), better quality of life (p=0.002), and fewer emergency department visits at one year. The number needed to test to achieve one clinically meaningful improvement was four. 4 / Promising

Coronary function testing is not experimental. It is not investigational. It is endorsed by the European Society of Cardiology guidelines for the evaluation of chronic coronary syndromes. Yet fewer than 20% of catheterization laboratories in the United States routinely offer it.

The test adds approximately fifteen minutes to a standard catheterization procedure. It requires acetylcholine and adenosine, both commonly available and inexpensive. It requires expertise in interpreting coronary flow reserve and vasoreactivity testing. The barrier is not technical. The barrier is conceptual. We have not yet reorganized catheterization laboratories around the understanding that non-obstructive disease is real disease.

If you are a woman undergoing catheterization for chest pain, request coronary function testing explicitly. The specific request is: acetylcholine provocation testing and adenosine coronary flow reserve measurement. If your interventionalist does not offer these tests, ask for referral to a center that does.

The Language of Advocacy: What to Say in the Exam Room

Structural barriers require structural solutions. Policy changes in catheterization referral practices, mandatory reporting of sex-disaggregated procedure rates, financial incentives for function testing. These changes take years.

You have an appointment next week. Here is what to say.

If your symptoms are being attributed to non-cardiac causes without objective testing: “What is my pretest probability of coronary artery disease? I would like to know the specific number.”

Pretest probability calculators exist. The Duke Clinical Score, the Framingham Risk Score, the HEART Pathway. Your physician can calculate your likelihood of obstructive coronary disease based on your age, sex, risk factors, and symptom characteristics. If that probability exceeds 15%, guidelines from the American College of Cardiology support non-invasive testing. If non-invasive testing is abnormal or inconclusive, catheterization is indicated.

If catheterization is declined despite abnormal testing: “Can you document in my chart the clinical reasoning for not proceeding with catheterization? I want to understand why my case differs from the guideline recommendations.”

Documentation requests are not confrontational. They are clarifying. A physician who documents their reasoning must articulate it explicitly. This often surfaces assumptions that deserve examination.

If you are scheduled for catheterization: “I request radial artery access. How many radial procedures has my operator performed in the past year?”

If your catheterization shows non-obstructive disease: “I would like coronary function testing with acetylcholine provocation and adenosine flow reserve measurement. If this laboratory does not offer these tests, can you refer me to one that does?”

Bring this article. Print it. Hand it to your physician. Information asymmetry favors the institution. Specific requests shift the balance.

Closing the Gap: What Must Change

The disparity in cardiac catheterization between women and men is not a mystery. It is not an unsolved problem awaiting new research. The mechanisms are identified. The solutions are known. Implementation is the barrier.

Referral algorithms must be audited for sex bias. Every catheterization laboratory should track the proportion of procedures performed in women versus the proportion of chest pain presentations in women. Discrepancies require investigation and correction.

Coronary function testing must become standard. Every patient, regardless of sex, who undergoes catheterization for chest pain and is found to have non-obstructive disease should receive acetylcholine provocation and adenosine flow reserve measurement. The finding of “normal coronaries” should trigger additional evaluation, not discharge.

Patient-reported symptoms must carry equal weight. The atypical presentation paradigm needs retirement. Women present differently because women’s cardiac physiology differs. Jaw pain, fatigue, nausea, and shortness of breath are not atypical. They are typical for women. The diagnostic criteria must expand to encompass this reality.

Training must address implicit bias. Medical students and residents must learn that the historical underrepresentation of women in cardiovascular trials created diagnostic frameworks biased toward male presentation. Awareness does not eliminate bias, but it creates the conditions for correction.

The woman I described at the opening survived her cardiac arrest. She underwent coronary stenting of her LAD lesion. She is alive and functional at eighteen months of follow-up. The four emergency department visits before her diagnosis, the four times she was reassured and discharged, the four opportunities for earlier intervention, these represent system failure. Her survival does not redeem that failure. It merely allows us to learn from it.

At your next visit, ask for these things by name: your pretest probability as a specific number, radial artery access if catheterization is indicated, and coronary function testing if your arteries appear non-obstructive. Print this article and bring it with you. The gap closes one informed patient at a time.

Frequently Asked Questions

Why are women less likely to be referred for cardiac catheterization?

The referral gap emerges from multiple converging factors. Women more often present with symptoms that differ from the classic male pattern of crushing substernal chest pain, leading clinicians trained on male-predominant data to underestimate disease probability. Implicit bias affects clinical decision-making even among well-intentioned physicians. The Shaw et al. JAMA study found that after controlling for objective measures of ischemia severity, women remained 40% less likely to receive catheterization referral. The bias operates at the level of pattern recognition rather than conscious discrimination, making it harder to identify and correct. Structured referral protocols that rely on objective criteria rather than gestalt clinical impression reduce this disparity.

Is cardiac catheterization riskier for women than men?

Yes, but the excess risk is modifiable. Women have two to four times higher rates of major bleeding and vascular access complications, primarily because their femoral arteries average 6.5 millimeters in diameter compared to 8.0 millimeters in men. Standard catheter sheaths occupy a larger proportion of the vessel lumen, increasing the risk of injury, dissection, and bleeding. Radial artery access reduces major vascular complications by 60% in women according to the RIVAL trial. Request radial access by name before your procedure. Ask your operator about their annual radial volume. Operators performing more than 200 radial procedures annually have the lowest crossover rates to femoral access. The higher complication rate is a reason to modify technique, not to withhold indicated procedures.

What does it mean if my catheterization shows no blockages?

A finding of non-obstructive coronary artery disease, meaning less than 50% stenosis in any major vessel, does not mean your coronary circulation is normal. It means the large arteries visible on angiography are not severely narrowed. Approximately half of women with chest pain and non-obstructive disease on angiography have either coronary microvascular dysfunction or epicardial coronary spasm, conditions that cause genuine myocardial ischemia but are invisible on standard imaging. The WISE study demonstrated that women with microvascular dysfunction have 2.5-fold higher cardiovascular event rates over five years. Request coronary function testing with acetylcholine provocation and adenosine flow reserve measurement. This testing can identify the physiological cause of your symptoms and guide targeted treatment.

How do I advocate for catheterization if my doctor is hesitant?

Ask for your pretest probability as a specific number. Pretest probability calculators incorporate your age, sex, risk factors, and symptom characteristics to estimate the likelihood that you have obstructive coronary disease. If that number exceeds 15%, American College of Cardiology guidelines support objective evaluation with stress testing. If stress testing is abnormal or inconclusive, catheterization is the next step. If your physician declines to proceed despite concerning symptoms or abnormal testing, request documentation of their clinical reasoning in your medical record. Bring a symptom diary that records the date, time, duration, and characteristics of each episode of chest discomfort. Specific documentation creates accountability and often surfaces assumptions that warrant reexamination.

What additional testing should women request during catheterization?

Request coronary function testing by name. The specific tests are acetylcholine provocation testing, which identifies epicardial coronary spasm, and adenosine coronary flow reserve measurement, which identifies microvascular dysfunction. The CorMicA trial demonstrated that patients who received these tests and diagnosis-guided treatment had significantly better angina control, quality of life, and fewer emergency department visits compared to standard care. These tests add approximately fifteen minutes to a standard catheterization procedure and use commonly available, inexpensive medications. Not all catheterization laboratories offer them. If your interventional cardiologist does not perform coronary function testing, request referral to a center that does. The diagnosis changes treatment. Microvascular dysfunction responds to medications that target endothelial function. Coronary spasm responds to calcium channel blockers and nitrates. Standard angiography alone cannot distinguish between these conditions.